Trials / Completed
CompletedNCT01217177
A Study of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for Locally Advanced Cervix Cancer
A Phase I Study of Oral Administration of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for the Treatment of Locally Advanced Cervix Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The cervix cancer is the second malignant neoplasia more common between women. The combined treatment involving chemotherapy and radiotherapy was defined as the standard. This study will evaluate the safety, toxicity and maximal tolerated dose (MTD) of everolimus in association with cisplatin and pelvic radiotherapy, in patients with squamous cells carcinoma of uterine cervix, in stages IIB and IIIB.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | everolimus |
Timeline
- Start date
- 2011-12-01
- Primary completion
- 2014-04-01
- Completion
- 2014-04-01
- First posted
- 2010-10-08
- Last updated
- 2015-04-03
Locations
2 sites across 1 country: Brazil
Source: ClinicalTrials.gov record NCT01217177. Inclusion in this directory is not an endorsement.